Table 5 Most common treatment-related treatment-emergent adverse events
Treatment-Related Adverse Event (> 2% of Atogepant-Treated Participants) | Randomized, Placebo-Controlled Trials | Long-term Safety Trials | ||||
|---|---|---|---|---|---|---|
Atogepant | Placebo (n = 408) | Atogepant 60 mg once daily (n = 1228) | Standard Care (n = 196) | |||
10 mg once daily (n = 314) | 30 mg once daily (n = 411) | 60 mg once daily (n = 417) | ||||
Constipation | 14 (4.5) | 20 (4.9) | 20 (4.8) | 3 (0.7) | 37 (3.0) | 3 (1.5) |
Nausea | 10 (3.2) | 15 (3.6) | 21 (5.0) | 6 (1.5) | 24 (2.0) | 9 (4.6) |
Fatigue | 4 (1.3) | 6 (1.5) | 9 (2.2) | 5 (1.2) | 14 (1.1) | 9 (4.6) |
Somnolence | 8 (2.5) | 5 (1.2) | 9 (2.2) | 4 (1.0) | 7 (0.6) | 5 (2.6) |